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To determine individual responses to ibuprofen gel or capsaicin cream for painful, radiographic knee 
osteoarthritis (OA) using a series of n-of-1 trials.  
Methods 
Twenty-two participants were allocated 5% ibuprofen gel (A) and 0.025% capsaicin cream (B) in random 
sequence (AB or BA). Patients underwent up to 3 treatment cycles, each comprising one treatment for 4 
weeks, an individualised washout period (maximum 4 weeks), then the other treatment for 4 weeks. 
Differential (ibuprofen or capsaicin) response was defined when change-from-baseline pain intensity scores (0-
10 NRS) differed by ≥1 between treatments in ≥2 cycles within a participant.  
Results 
104 treatment periods were aggregated. Mean pain reduction was 1.2 (95%CI 0.5 to 1.8) on ibuprofen and 1.6 
(95%CI 0.9 to 2.4) on capsaicin (p=0.221).  Of 22 participants, 4 (18%) had a greater response to ibuprofen, 9 
(41%) to capsaicin, 4 (18%) had similar responses, and 5 (23%) were undetermined.  
Conclusions 
Irrespective of equal efficacy overall, 59% of people displayed a greater response to one treatment over the 
other. Patients that do not benefit from one type of topical treatment should be offered to try another, which 
may be more effective. N-of-1 trials are useful to identify individual response to treatment. 
Clinical trial registration 
NCT03146689 on clinicatrials.org 
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Key messages (max 15 words each) 
1. Response to topical NSAIDs and capsaicin varies between individuals 
2. Over half of people with knee OA respond better to one treatment over the other 
3. Application of an effective treatment should be tailed to individual  responses 







Topical non-steroidal anti-inflammatory drugs (NSAIDs) and capsaicin are commonly recommended and 
effective treatments for pain relief in osteoarthritis (OA).(1, 2) Whilst topical NSAIDs reduce pain primarily 
through cyclo-oxygenase (COX) inhibition,(3) capsaicin, the principal warming component of chilli peppers, is 
thought to act by defunctionalisation of spontaneously active nociceptors.(4) Despite reliance on 
mechanistically disparate methods for pain relief, indirect study-level evidence through network meta-analysis 
indicates that the treatments are equally effective overall for pain relief in OA.(2) No head-to-head comparison 
of individual or average responses to the treatments is currently available. However, it is hypothesised that 
despite the study-level equivalence, treatment efficacy varies between individuals as anecdotally observed in 
clinical practice. 
Evidence synthesis for treatment efficacy has largely focused on average treatment effects, but in order to 
improve care it is important to also examine individual responses to treatment. This is the basis of precision 
medicine, and the movement away from a “one size fits all” approach to individual patient management. N-of-
1 trials, or single participant randomised trials, have previously been used to establish the relative efficacy 
between treatments using within-person comparisons ).(5, 6) However, perhaps the greatest benefit of this 
design is that it allows examination of individual responses to different treatments, and can therefore help 
optimise treatment at an individual level.(7) The present study aimed to determine individual responses to 




This was a randomised, open label series of n-of-1 trials. The study was approved by the Faculty of Medicine 
and Health Sciences Research Ethics Committee of the University of Nottingham (reference no. B10022017) 
and registered with ClinicalTrials.gov (NCT03146689). The final approved protocol, participant information 
sheet, and consent form are available online 
(https://www.nottingham.ac.uk/research/groups/osteoarthritisandcrystalarthritis/studies/index.aspx).  
Participants underwent up to three treatment cycles (six treatment periods; Figure 1). Each treatment cycle 
consisted of two treatment periods of ibuprofen gel and capsaicin cream in a randomised order. Treatment 
periods were four weeks and were separated by a washout period until the participant felt their knee pain had 
returned to its usual pre-treatment level or to a maximum of four weeks. An interim analysis was conducted 
for each participant at the end of the second cycle to determine treatment response. Those who met the pre-
specified response criteria (i.e., showed the same response in two cycles) were given the option to complete 
the study at that point. The n-of-1 trials were aggregated into a series. 
Randomisation was conducted using a web-based programme (www.randomizer.org) by a researcher not 
involved in participant recruitment, enrolment, assessment, or outcome collection. Randomisation data were 
kept strictly confidential and treatment allocation was recorded in sequentially numbered, sealed, opaque 
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envelopes. Participants were sequentially allocated to the next assigned envelope at the beginning of each 
treatment cycle. Participants and research staff were not blinded to the treatments due to the initial warming 
sensation and erythema often experienced with capsaicin and the different appearance and amounts of 
applied treatment.  
Participants 
Participants were recruited from the Nottingham Knee Pain and Health in the Community (KPIC) cohort study 
from the East Midlands region of the UK.(8) Inclusion criteria were men and women aged 40 years and over 
with chronic knee pain and radiographic knee OA (i.e. definite narrowing and definite osteophyte in the 
tibiofemoral and/or patellofemoral compartments as per Nottingham line drawing atlas scoring)(9, 10). 
Participants scoring between 4 and 8, inclusive, on the 0-10 numeric rating scale (NRS) for knee pain intensity 
in the index knee were eligible. The most painful knee was determined to be the index knee for local 
assessments and questionnaire responses.   
Exclusion criteria were: inability to give informed consent; terminal or untreated major mental illness; 
pregnancy or breastfeeding; daily use of oral NSAID in  the last two weeks; prior regular use of ibuprofen gel or 
capsaicin cream on the affected knee(s); hypersensitivity or allergy to the interventions or other ingredients in 
the preparations; total joint replacement of the affected joint; current treatment for stomach or duodenal 
ulcers; renal failure; or current treatment with anticoagulants.  
Interventions 
Participants received 5% w/w ibuprofen gel (Care, Thornton and Ross Limited) and 0·025% w/w capsaicin 
cream (Zacin, Cephalon UK Limited). The medications were applied four times per day to the painful knee(s). 
The recommended doses were an extruded inch of ibuprofen gel and a pea-sized amount of capsaicin cream. 
Participants continued to use their regular medications, including oral analgesics, throughout the trial provided 
the frequency/dose had remained stable for three months. Non-permitted concomitant therapies were 
additional topical analgesics for the affected knee, regular oral NSAIDs, joint injection, or surgery.  
Outcome measures 
Participants recorded pre- and post-treatment pain intensity scores in their index knee for each treatment 
period using 0-10 NRS (0 – “no pain” to 10 – “worst imaginable pain”). Change-from-baseline pain scores were 
calculated per period.  
Baseline characteristics assessed prior to randomisation were: age, sex, and obesity; knee pain intensity (0-10 
NRS) and neuropathic-like knee pain (modified painDETECT questionnaire(11)); function (activities of daily 
living domain of the Knee Injury and Osteoarthritis Outcome Score questionnaire (12)); illness perception 
(modified Brief Illness Perception Questionnaire (13)); expectation of treatment (13); anxiety and depression 
(Hospital Anxiety and Depression Scale (14)); fibromyalgia (15); central pain mechanism traits (16); 
inflammation (knee ultrasound: synovial thickness, effusion, and power Doppler signal); abnormal pain 
processing (quantitative sensory testing: pressure pain thresholds [PPTs] and temporal summation [TS]); 
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quadriceps muscle strength; and radiographic severity from radiographs obtained at varying time-points within 
the previous two years.(8) 
Sample size 
The n-of-1 trials consisted of three treatment cycles (six paired periods). Three cycles is the commonest 
number of cycles used in n-of-1 trials in OA and other conditions.(5, 6, 17) After the first few cycles, each 
additional cycle contributes little to the precision of the trial.(18) Three cycles were therefore felt to provide 
sufficient data without lengthening the trial beyond 44 weeks, thereby maintaining trial eligibility and 
participant retention.  
 The sample size of the n-of-1 trial series was subsequently based on the number of treatment periods rather 
than participants. In order to detect a minimum clinically important difference (MCID) of 0.5 SD between 
treatments, if there was any, 66 participants were required in a traditional parallel comparison trial, 33 in a 
cross-over trial, or 11 in a series of n-of-1 trials with three cycles under the assumption of no carry-over and 
period effects. This would give 80% power at a significance level of 0.05 for the trial. Assuming only 50% of 
participants showed a differential response between treatments, 22 participants were required.  
Statistical methods 
Categorical variables were reported as frequencies and continuous variables as mean and SD (if normally 
distributed) or median and inter quartile range (IQR) (if not normally distributed). Statistical significance was 
set at p<0·05. 
A difference of 1 point on 0-10 NRS was determined to be the threshold for clinically important pain relief. This 
is a conservative estimate of the MCID (0.5 SD) used by NICE OA guidelines(1) and reflects a “slightly better” 
change in status.(19)  
Each participant’s treatment response was determined by comparing the change-from-baseline scores for 
ibuprofen and capsaicin per cycle. A difference of ≥1 point between the treatments indicated a better 
response for one treatment over the other within the cycle. If a participant displayed the same differential 
response in two or more cycles, the overall differential treatment response was established for that 
participant, otherwise they were established as having an equal response. If the participant withdrew prior to 
meeting the above criteria, their response was “undetermined”.  
 
 The mean treatment effect was determined using in a three-level model, clustered at the cycle, period- and 
participant-level. End-of-period pain scores were the dependent variable and adjustment was undertaken for 
period baseline pain scores. Fixed treatment (ibuprofen=0 and capsaicin=1) were assumed. The significance of 
period and treatment sequence effects were examined through the addition of a treatment-by-period or 
treatment-by-sequence interaction term (fixed effect). One interaction was examined per model.  
A sensitivity analysis was conducted to exclude participant pain levels remaining outside the pre-specified 
inclusion criteria (4-8 NRS) after four weeks washout. For this, all periods where baseline pain was not within 
4-8 points (inclusive) were excluded from the multilevel regression modelling.  
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Analyses were conducted in Stata version 15.  
Results 
Between August 2017 and December 2018, 22 participants were enrolled and completed at least one 
treatment cycle (Figure 2). Five participants withdrew before trial completion: 3 due to erythema and skin 
irritation following ibuprofen gel use, one withdrew consent, and one died during the third washout period. 
Cause of death (ischaemic and hypertensive heart disease) was deemed unrelated to the study medications. 
Baseline characteristics of all participants are presented in Table 1.  
[ Table 1 ] 
Average level of pain reduction for topical ibuprofen versus capsaicin 
In the 104 completed treatment periods, mean pain reductions were 1.2 (95%CI 0.5 to 1.8) for ibuprofen and 
1.6 (95%CI 0.9 to 2.4) for capsaicin (p-value for difference = 0.271). No significant period or treatment 
sequence effects were identified (-0.07, 95%CI -0.42 to 0.28, p=0.691 and 0.15, 95%CI -0.88 to 1.19, p=0.773, 
respectively). 
Pain levels returned to 4-8 points (inclusive) after the washout for 71% of treatment periods. For the periods 
where pain levels did not return to 4-8 points after washout, 21% were >8 points and 79% were <4 points. No 
difference was found between topical NSAIDs and capsaicin in the sensitivity analysis limited only to periods 
where pre-treatment pain was 4-8 NRS (n=22, 80 periods, p=0.068). 
Individual responses to treatment 
Treatment responses favoured topical ibuprofen in four participants (18%), capsaicin in nine (41%), and found 
no difference in four (18%). Five participants (23%) withdrew prior to a response being established 
(`undetermined’). Pre-treatment characteristics of patients favouring ibuprofen versus capsaicin are presented 
in Table 1, and some variation in baseline characteristics is seen between the groups.  
Discussion 
This is the first n-of-1 trial series aiming to identify individual responses to topical NSAIDs and capsaicin.  We 
found that irrespective of the average equivalence between the treatments, more than half of individuals 
(59%) responded better to one treatment over the other. This suggests that it is feasible to use n-of-1 trials to 
examine individual responses to treatment.   
The best evidence available thus far for the relative efficacy of topical NSAIDs and capsaicin in OA concluded 
that they provide equal levels of pain relief.(2) However, in order to provide evidence to guide a clinician’s 
question about an individual, there is a need to move away from group averages and towards individual 
responses.(20, 21) Unlike between-group comparisons, such as randomised controlled trials, n-of-1 trials 
determine the difference between treatments within an individual. They are therefore optimal for precision 
medicine. Treatments are repeated randomly in order to establish individual treatment responses. Cases can 
be accumulated gradually to the number sufficient to examine overall treatment responses or for the analysis 
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of predictors of response. Over half of participants in the present study had a clinically important greater 
response to one treatment over the other, suggesting that this study design is able to differentiate treatment 
responses, even when two treatments are equally effective in between-group comparisons. 
For precision medicine to be implemented, three conditions need to be met: [1] the disease must be variable 
due to a multifactorial aetiology; [2] there must exist several treatment options for which there are 
heterogeneous responses; and [3] a clinical biomarker, indicating a differential response for a certain 
treatment in a patient subpopulation, must be identified.(22) It is widely accepted that OA is a heterogeneous 
condition and this is reflected in the baseline characteristics of the trial population. Over 50 therapies are 
available for OA(23) but the present study focused on two widely available topical therapies. Heterogeneous 
responses to the topical treatments were identified in the present work. Finally, examination of baseline 
characteristics according to treatment response indicate that there may be sufficient variation in pre-
treatment responses to search for clinical biomarkers. A large and adequately powered n-of-1 trial may be 
used to establish clinical biomarkers.   
The present work is subject to limitations. First, baseline pain levels remained low for some participants 
despite four weeks’ washout. This may be due to (1) insufficient washout durations, (2) the Hawthorne effect, 
i.e., alterations in behaviour as a result of being observed, (3) regression to the mean, (4) natural fluctuations 
in osteoarthritis pain, or (5) the effect of potential lifestyle changes during the long observation period. 
Adjustment for baseline pain allowed this to be accounted for in the comparison of the average pain reduction 
between treatments. In addition, we conducted a sensitivity analysis restricted to periods where baseline pain 
scores were 4-8 and found that this did not significantly alter the findings. Secondly, imbalances in the 
differential treatment response of the drop-outs may have biased the examination of pre-treatment 
characteristics. 80% of drop-outs displayed greater treatment response to ibuprofen in their first cycle, but 
were not classified as ibuprofen responders as they withdrew prior to meeting response criteria. However, the 
purpose of repeatedly comparing treatments in multiple cycles is to establish differential treatment response. 
Taking only one cycle makes the findings more prone to bias. This is why we chose to classify this group as 
“undetermined”. Thirdly, participants and trial personnel were not blinded. Due to inherent difficulties in 
blinding capsaicin and to more closely reflect clinical care, the trial was open label. However, this reflects 
clinical practice, where the patient and clinician are not blinded when selecting optimal treatments. Finally, 
although n-of-1 trials require fewer participants for aggregated analysis and for separation between response 
and non-response, a larger sample size is needed to compare the characteristics between responders and non-
responders. Further study in this regard is useful. 
In conclusion, despite topical NSAIDs and capsaicin being equally effective across the whole population, 
treatment responses varied between individuals with painful knee OA.  Over half of participants showed a 
greater response to one treatment over the other. Where one topical treatment provides insufficient pain 
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Table 1. Pre-treatment characteristics of the 22 participants enrolled in the n-of-1 trial series, and separately 






  Ibuprofen (n=4) Capsaicin (n=9) 
Basic demographics    
Age; mean (SD), years 67.0 (9.3) 67.6 (2.2) 63.8 (12.5) 
Sex; n (%) women 12 (55%) 1 (25%) 7 (78%) 
BMI; mean (SD), kg/m2 30.7 (5.6) 27.9 (1.6) 32.3 (7.1) 
Questionnaire – comorbidities    
Anxiety; n (%) HADS anxiety subscale ≥ 8 9 (40.9%) 1 (25.0%) 4 (44.4%) 
Depression; n (%) HADS depression subscale ≥ 8 4 (18.2%) 1 (25.0%) 2 (22.2%) 
Fibromyalgia; n (%) criteria met 2 (9.1%) 0 (0%) 2 (100.0%) 
Questionnaire – OA features     
Index knee; n (%) left knee pain 11 (50.0%) 2 (50.0%) 5 (55.5%) 
Baseline pain; median (IQR), NRS severity 5.5 (4.0 to 7.0) 6.5 (6.0 to 7.5) 5.0 (4.0 to 7.0) 
Neuropathic-like pain;    
 n (%) with definite NP (PDQ ≥ 19) 3 (13.6%) 0 (0%) 2 (22.2%) 
 n (%) with definite or possible NP (PDQ ≥ 13) 7 (31.8%) 0 (0%) 5 (55.5%) 
Physical function; median (IQR), KOOS 58.1 (47.1 to 73.5) 55.9 (51.5 to 66.2) 58.8 (48.5 to 73.5) 
Central Mechanisms trait; median (IQR), range (0-24) 9.4 (7.8 to 14.3) 9.0 (7.8 to 11.5) 10.8 (9.0 to 14.3) 
Examination findings (index knee)    
Static quadriceps strength; median (IQR), kg 16.1 (14.3 to 21.0) 24.4 (17.6 to 27.9) 16.0 (14.5 to 19.4) 
Radiographic severity    
 Total NLDA score; median (IQR) 13 (9 to 18) 13 (10 to 17) 14 (6 to 20) 
 NLDA osteophyte score; median (IQR)* 9 (5 to 15) 8 (6 to 11) 9 (3 to 16) 
 NLDA JSN score; median (IQR) 4 (3 to 5) 5 (4 to 7) 4 (3 to 5) 
 n (%) per tibiofemoral KL grade     
    0 2 (9%) 1 (25%) 0 (0%) 
    1 3 (14%) 1 (25%) 2 (22%) 
    2 7 (32%) 2 (50%) 3 (33%) 
    3 9 (41%) 0 (0%) 3 (33%) 
    4 1 (5%) 0 (0%) 1 (11%) 
 n (%) per patellofemoral KL grade     
    0 4 (19%) 0 (0%) 4 (44%) 
    1 9 (43%) 2 (50%) 2 (22%) 
    2 3 (14%) 0 (0%) 1 (11%) 
    3 5 (24%) 2 (50%) 2 (22%) 
US features    
 Synovial thickness; mean (SD), mm 5.52 (2.93) 6.48 (1.43) 3.96 (3.16) 
 n (%) with SH (SH ≥ 4mm) 15 (68.2%) 4 (100%) 4 (44.4%) 
 Effusion; mean (SD), mm 8.9 (3.65) 8.4 (3.7) 8.5 (4.0) 
 n (%) with effusion (effusion ≥ 4 mm) 21 (94.5%) 4 (100%) 8 (88.9%) 
 n (%) Power Doppler positive 3 (13.6%) 1 (25%) 0 (0%) 
QST features    
 Localised PPT (MJL); median (IQR), kPa 393.0 (154.4 to 610.6) 424.6 (223.4 to 664.0) 342.7 (151.6 to 610.6) 
 Distal PPT (proximal tibia); median (IQR), kPa 390.6 (200.0 to 529.6) 390.9 (163.4 to 733.4) 411.8 (200.0 to 518.8) 
 Remote PPT (sternum); median (IQR), kPa 280.9 (137.7 to 401.2) 282.6 (131.3 to 422.0) 287.2 (118.8 to 430.5) 
 TS; mean (SD), 0-100 NRS 37.9 (24.2) 44.4 (33.8) 34.5 (22.2) 
*Skyline views were not available for one participant for whom an aggregated osteophyte score was not calculated. 
Osteophyte scores in the available graded compartment were ≥2 
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; IQR, interquartile range; KL, Kellgren-Lawrence; KOOS, 
Knee Injury and Osteoarthritis Outcome Score; MJL, medial joint line; NLDA, Nottingham Line Drawing Atlas; NP, neuropathic 
pain; NRS, numeric rating scale; OA, osteoarthritis; PDQ, painDETECT questionnaire; PPT, pressure pain detection threshold; 





Figure 1. N-of-1 trial design showing a hypothetical random treatment sequence for capsaicin cream (C) and 
ibuprofen gel (I). Treatment periods were four weeks’ duration and washout periods were variable in length 
(until pain returned to pre-treatment levels, up to a maximum of four weeks) 
Figure 2. Flow of subjects through the trial. Individual treatment responses were established for the 17 
participants that completed the trial. Multilevel modelling for average treatment effects were conducted in all 







































































































Assessed for eligibility (n=122)
Randomised (n=22)
Allocated treatment (n=22)
Treatment response established (n=17)
Analysed in multilevel modelling (n=22)
Excluded (n=100)
• Declined to participate: 81
• Did not meet inclusion criteria: 19
Did not complete trial (n=5)
• Treatment-related AE: 3
• Death (unrelated): 1
• Consent withdrawn: 1
Enrolment
Allocation
Follow-up
Analysis
